Compare BIRK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIRK | PCVX |
|---|---|---|
| Founded | 1774 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 7.0B |
| IPO Year | 2023 | 2020 |
| Metric | BIRK | PCVX |
|---|---|---|
| Price | $33.49 | $56.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | $61.43 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.71 | N/A |
| Revenue Next Year | $14.30 | N/A |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.93 | $33.62 |
| 52 Week High | $50.73 | $65.00 |
| Indicator | BIRK | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 40.28 |
| Support Level | $33.06 | $52.18 |
| Resistance Level | $37.29 | $58.77 |
| Average True Range (ATR) | 1.08 | 2.10 |
| MACD | 0.44 | -0.48 |
| Stochastic Oscillator | 80.36 | 21.28 |
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.